TC Biopharm (Holdings) logo

TC Biopharm (Holdings)NASDAQ: TCBP

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United Kingdom

IPO:

11 February 2022

Website:

http://www.tcbiopharm.com

Next earnings report:

N/A

Last dividends:

N/A

Next dividends:

N/A

Market cap

$4.15 M
-99%vs. 3y high
10%vs. sector

PE ratio

0.87
-56%vs. 3y high
2%vs. sector

PB ratio

3.05
-99%vs. 3y high
71%vs. sector

PS ratio

-
-vs. 3y high
-vs. sector

Price

after hours | Fri, 28 Jun 2024 23:50:06 GMT
$0.84-$0.09(-9.68%)

Dividend

No data over the past 3 years

EPS diluted

EPS diluted target

-$2.79-

Revenue

Revenue target

--

Revenue

Net income

--$4.21 M

Analysts recommendations

Total assets

Total liabilities

$9.17 M$7.81 M

Institutional Ownership

Included in screeners

Small cap companies
Worst performing stocks today
Stocks under 1$
Stocks with high beta
Stocks with price below SMA 200
Growing shares outstanding

Similar companies

Catheter Precision (VTAK)

Predictive Oncology logo

Predictive Oncology (POAI)

Virios Therapeutics logo

Virios Therapeutics (VIRI)

Palisade Bio logo

Palisade Bio (PALI)

MyMD Pharmaceuticals logo

MyMD Pharmaceuticals (MYMD)

Portage Biotech logo

Portage Biotech (PRTG)

Theriva Biologics logo

Theriva Biologics (TOVX)

Protagenic Therapeutics logo

Protagenic Therapeutics (PTIX)

TCBP Latest News

Why Is TC Biopharm (TCBP) Stock Up 51% Today?
InvestorPlace06 May 2024 Sentiment: POSITIVE

TC BioPharm (NASDAQ: TCBP) stock is surging today following the announcement of a significant acquisition deal with a private biotechnology company specializing in CAR-T therapies.

TC BioPharm (TCBP) Falls Despite FDA Clearing IND for AML Drug
Zacks Investment Research28 November 2023 Sentiment: NEGATIVE

The FDA clears TC BioPharm's (TCBP) investigational new drug application seeking approval to begin a clinical study on its pipeline candidate, TCB008, for treating acute myeloid leukemia. Stock declines.

What type of business is TC Biopharm (Holdings)?

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

What sector is TC Biopharm (Holdings) in?

TC Biopharm (Holdings) is in the Healthcare sector

What industry is TC Biopharm (Holdings) in?

TC Biopharm (Holdings) is in the Biotechnology industry

What country is TC Biopharm (Holdings) from?

TC Biopharm (Holdings) is headquartered in United Kingdom

When did TC Biopharm (Holdings) go public?

TC Biopharm (Holdings) initial public offering (IPO) was on 11 February 2022

What is TC Biopharm (Holdings) website?

https://www.tcbiopharm.com

Is TC Biopharm (Holdings) in the S&P 500?

No, TC Biopharm (Holdings) is not included in the S&P 500 index

Is TC Biopharm (Holdings) in the NASDAQ 100?

No, TC Biopharm (Holdings) is not included in the NASDAQ 100 index

Is TC Biopharm (Holdings) in the Dow Jones?

No, TC Biopharm (Holdings) is not included in the Dow Jones index

When does TC Biopharm (Holdings) report earnings?

Next earnings report date is not announced yet